Drug Profile


Alternative Names: GT 2331; Perceptin

Latest Information Update: 23 Dec 2003

Price : $50

At a glance

  • Originator Gliatech (CEASED)
  • Class Antidementias; Antihistamines; Neuroprotectants; Small molecules
  • Mechanism of Action Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Suspended Alzheimer's disease; Attention-deficit hyperactivity disorder; Cognition disorders; Sleep disorders

Most Recent Events

  • 23 Dec 2003 Suspended - Phase-I for Alzheimer's disease in USA (PO)
  • 23 Dec 2003 Suspended - Phase-II for Sleep disorders in USA (PO)
  • 23 Dec 2003 Suspended - Phase-II for Cognition disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top